市場調査レポート

商品コード

1445539

mTOR阻害剤の世界市場の評価：タイプ・用途・エンドユーザー・地域別の機会および予測 (2017年～2031年)

mTOR Inhibitors Market Assessment, By Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月07日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 223 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のmTOR阻害剤の市場規模は、2024年から2031年の予測期間中にCAGR 5.1％を記録し、2023年の50億3,000万米ドルから、2031年には74億9,000万米ドルの規模に成長すると予測されています。

癌、移植手術、自己免疫疾患に対する効果的な治療法へのニーズの高まりから、市場は大幅な成長と技術革新を経験しています。

エベロリムスやテムシロイイムスなどのmTOR阻害剤は、神経内分泌腫瘍、乳癌、腎細胞癌など、さまざまな癌の治療に優れた効果を発揮しています。自己免疫疾患や癌に罹患しやすい老齢人口が増加しているため、mTOR阻害剤の必要性は高まっています。

mTOR阻害剤のもう一つの重要な用途は免疫抑制と臓器移植です。免疫系を阻害することで、これらの薬剤は臓器拒絶反応の回避を助け、移植手術の成功率を高めます。さらに、R&Dへの継続的な取り組みにより、関節リウマチやループスなど他の自己免疫疾患へのmTOR阻害剤の適応の可能性が広がっており、新たな市場機会を示唆しています。

癌罹患率の上昇が市場シェアに貢献

mTOR阻害剤の市場は癌の有病率の増加により急成長しています。世界保健機関 (WHO) の推計によると、癌は世界第2位の死因であり、医療管理機関の最優先課題の1つとなっています。癌の患者数は毎年急ピッチで増加しています。エベロリムスやテムシロリムスなどのmTOR阻害剤は、神経内分泌腫瘍、乳癌、腎細胞癌など、さまざまな種類の癌の治療に顕著な効果があることが証明されています。

mTOR阻害剤の多様な用途

mTOR阻害剤の多用途性は、治療用途の拡大とともに、世界のmTOR阻害剤市場の成長を牽引する重要な動向となっています。当初、mTOR阻害剤は癌治療に大きな影響を与えることが認識されていましたが、より広範な疾患に対する研究が活発に行われています。潜在的な適応範囲が広がったことで、mTOR阻害剤市場への関心と投資が高まり、市場の潜在力が強化されています。最近の科学的な取り組みにより、ループスや関節リウマチなどのさまざまな自己免疫疾患におけるmTOR経路の役割が明らかになってきました。

臓器移植の増加

毎年多くの命を救う重要な医療処置が臓器移植であり、これが世界のmTOR阻害剤市場の成長を促進する大きな要因となっています。移植患者の数は増加しており、それに伴ってmTOR阻害剤のような効率的な免疫抑制剤の需要も増加しています。

当レポートでは、世界のmTOR阻害剤の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
タイプ別
- ラパミューン
- アフィニター
- トリセル
- ゾートレス
- オミパリシブ
- その他
用途別
- 癌
- 免疫抑制
- 臓器移植
- その他
エンドユーザー別
- 病院薬局
- 小売薬局
- オンライン薬局
- その他
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界のmTOR阻害剤市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

タイプ別
用途別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需要供給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)
特許分析 (該当する場合)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

AbbVie Inc.
Astra Zeneca PLC
Bayer AG
Boehringer Ingelheim International Gmbh
Abott Inc.
Bristol-Myers Squibb Co
Pfizer Inc.
Merck & Co., Inc.
Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
F. Hoffmann-La Roche Ltd
Novartis AG
Sanofi S A
Eisai Co. Ltd

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 3. Global MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 4. Global MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 5. Global MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 6. Global MTOR Inhibitors Market Share (%), By Region, 2017-2031F
Figure 7. North America MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 9. North America MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 10. North America MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 11. North America MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 12. North America MTOR Inhibitors Market Share (%), By Country, 2017-2031F
Figure 13. United States MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 15. United States MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 16. United States MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 17. United States MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 18. Canada MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 20. Canada MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 21. Canada MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 22. Canada MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 23. Mexico MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 25. Mexico MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 26. Mexico MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 27. Mexico MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 28. Europe MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 30. Europe MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 31. Europe MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 32. Europe MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 33. Europe MTOR Inhibitors Market Share (%), By Country, 2017-2031F
Figure 34. Germany MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 36. Germany MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 37. Germany MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 38. Germany MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 39. France MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 40. France MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 41. France MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 42. France MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 43. France MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 44. Italy MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 46. Italy MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 47. Italy MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 48. Italy MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 49. United Kingdom MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 51. United Kingdom MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 52. United Kingdom MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 53. United Kingdom MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 54. Russia MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 56. Russia MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 57. Russia MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 58. Russia MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 59. Netherlands MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 61. Netherlands MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 62. Netherlands MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 63. Netherlands MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 64. Spain MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 66. Spain MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 67. Spain MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 68. Spain MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 69. Turkey MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 71. Turkey MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 72. Turkey MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 73. Turkey MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 74. Poland MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 76. Poland MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 77. Poland MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 78. Poland MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 79. South America MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 81. South America MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 82. South America MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 83. South America MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 84. South America MTOR Inhibitors Market Share (%), By Country, 2017-2031F
Figure 85. Brazil MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 87. Brazil MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 88. Brazil MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 89. Brazil MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 90. Argentina MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 92. Argentina MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 93. Argentina MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 94. Argentina MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 95. Asia-Pacific MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 97. Asia-Pacific MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 98. Asia-Pacific MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 99. Asia-Pacific MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 100. Asia-Pacific MTOR Inhibitors Market Share (%), By Country, 2017-2031F
Figure 101. India MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 102. India MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 103. India MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 104. India MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 105. India MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 106. China MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 107. China MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 108. China MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 109. China MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 110. China MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 111. Japan MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 113. Japan MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 114. Japan MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 115. Japan MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 116. Australia MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 118. Australia MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 119. Australia MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 120. Australia MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 121. Vietnam MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 123. Vietnam MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 124. Vietnam MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 125. Vietnam MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 126. South Korea MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 128. South Korea MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 129. South Korea MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 130. South Korea MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 131. Indonesia MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 133. Indonesia MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 134. Indonesia MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 135. Indonesia MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 136. Philippines MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 138. Philippines MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 139. Philippines MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 140. Philippines MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 141. Middle East & Africa MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 143. Middle East & Africa MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 144. Middle East & Africa MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 145. Middle East & Africa MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 146. Middle East & Africa MTOR Inhibitors Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 149. Saudi Arabia MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 150. Saudi Arabia MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 151. Saudi Arabia MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 152. UAE MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 154. UAE MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 155. UAE MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 156. UAE MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 157. South Africa MTOR Inhibitors Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa MTOR Inhibitors Market, By Volume, in Thousand Units, 2017-2031F
Figure 159. South Africa MTOR Inhibitors Market Share (%), By Type, 2017-2031F
Figure 160. South Africa MTOR Inhibitors Market Share (%), By Application, 2017-2031F
Figure 161. South Africa MTOR Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11088

Global mTOR inhibitors market is projected to witness a CAGR of 5.1% during the forecast period 2024-2031, growing from USD 5.03 billion in 2023 to USD 7.49 billion in 2031. Due to the growing need for effective therapies for cancer, transplant procedures, and autoimmune illnesses, the market has experienced significant expansion and innovation over the historic period.

mTOR (mammalian target of rapamycin) inhibitors are essential for treating cancer, and suppressing the immune system, and are used to treat other medical conditions as well. The increasing incidence of cancer globally is one of the main factors driving the growth of the global market for mTOR inhibitors. mTOR inhibitors, including everolimus and temsiroIimus, have demonstrated exceptional effectiveness in treating a variety of cancers, including neuroendocrine tumors, breast cancer, and renal cell carcinoma. The need for mTOR inhibitors has increased due to the rising geriatric population, who are more prone to autoimmune disorders and cancer.

Another important application of mTOR inhibitors is immunosuppression and organ transplantation. By inhibiting the immune system, these medications assist in avoiding organ rejection and increase the success rates of transplant procedures. Additionally, continued research and development initiatives are broadening the potential application of mTOR inhibitors in other autoimmune conditions such as rheumatoid arthritis and lupus, suggesting new market opportunities.

Rising Prevalence of Cancer Contributes to the Market Share

The market for mTOR inhibitors is growing at a rapid pace due to the increasing prevalence of cancer. The World Health Organization (WHO) estimated that cancer is the second biggest cause of death worldwide, making it one of the highest priorities of healthcare governing bodies. The number of cancer cases is growing at a rapid pace each year. As the global population grows older, they are prone to develop cancer. mTOR inhibitors, like everolimus and temsirolimus, have proven to be remarkably effective in treating a variety of cancer types, including neuroendocrine tumors, breast cancer, and renal cell carcinoma.

mTOR inhibitors have shown promising results in restraining tumor progression. Their ability to specifically target cellular pathways makes them a good treatment option for cancer, particularly in cases where traditional therapies may be less effective. Indian Council of Medical Research (ICMR) stated that the country's average cancer case count for 2022 was 100.4 per 100,000 people, with a high proportion of women (estimated at 105.4 per 100,000) receiving a breast cancer diagnosis. Based on the data from Cancer Research UK, more than 27.5 million new cancer cases are expected globally by 2040.

Multiple Uses of mTOR Inhibitors

The versatility of mTOR inhibitors, with their expanding therapeutic applications, represents a significant trend driving the growth of the global mTOR inhibitors market. Initially recognized for their profound impact on cancer treatment, mTOR inhibitors are being actively researched for a broader spectrum of diseases. The broadening scope of potential applications is attracting increased interest and investment in the market, bolstering its potential. Recent scientific endeavors have shed light on the role of mTOR pathways in various autoimmune diseases, such as lupus and rheumatoid arthritis.

Preliminary results from clinical trials and studies indicate positive outcomes, with mTOR inhibitors showing positive results in reducing disease activity and improving patient's quality of life. Also, potential applications of mTOR inhibitors in neurodegenerative diseases, metabolic disorders, and certain rare diseases are being discovered through research. As scientists continue to explore treatment methodologies by mTOR inhibitors and their role in various diseases, the application of mTOR inhibitors will expand.

Moreover, the expansion in therapeutic applications translates to a more diversified market, attracting pharmaceutical companies to invest in research and development initiatives centered on mTOR inhibitors. In April 2022, Nobelpharma America became the first company to receive FDA approval for a topical treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC). The approval covers a topical gel formulation of sirolimus, an mTOR inhibitor also known as rapamycin.

Increasing Volume of Organ Transplantations

An important medical procedure that saves many lives every year is organ transplantation, which is a major factor propelling the growth of the global mTOR inhibitors market. The number of transplant patients has increased, and with it the increased demand for efficient immunosuppressive medications such as mTOR inhibitors.

mTOR inhibitors are essential for post-transplant treatment as they suppress the immune system and reduce the chance of organ rejection. Their value lies in their capacity to target immune cells that cause organ rejection while sparing others, to preserve the organs' long-term viability after transplantation. In addition, mTOR inhibitors have become well-known in the transplant community due to their comparative benign adverse effect profile when compared to certain immunosuppressant medications that came earlier. Therefore, mTOR inhibitors are more widely accepted and used in transplantation protocols, which is supporting the global mTOR inhibitor market. In 2021, 13,861 people nationwide donated their organs after their death, according to the US Department of Health and Human Services and the Health Resources and Services Administration. The number broke the record for deceased donations for the eleventh year in a row and was increased by 10.1% over the previous year, or 2020. In May 2021, the weekly total of deceased donors surpassed 300 for the first time, in June 2021, the 300-donor threshold was surpassed twice.

Rapamycin Dominates The Drug Type Segment

Rapamycin, also known as Sirolimus, differs from other calcineurin inhibitors like tacrolimus and cyclosporine because of the way it targets mTOR. The signaling system of the mammalian target of rapamycin (mTOR) is linked to the development of several illnesses, including cancer, neurological diseases, genetic disorders, and obesity, as it regulates cell growth and proliferation. Since sirolimus targets mTOR, which is involved in many essential biological processes, it has a wide range of therapeutic uses outside of organ transplantation. In addition to being utilized in organ transplantation, the medication can be used to coat coronary stents to prevent the body's system from rejecting newly donated organs and to treat lymphangioleiomyomatosis, a rare lung condition. The increasing popularity of Sirolimus coated balloons for treating peripheral vascular disease in western countries has come out as new advancement. Patients are benefiting from the treatment method and is being considered an effective approach.

North America Dominates mTOR Inhibitor Market

North America dominates the global mTOR inhibitor market, due to factors such as a high number of cancer patients, increasing geriatric population, innovations, and advancements in cancer therapeutics and treatment. Modern hospitals, academic institutions, and a highly qualified healthcare workforce defines North America's advanced and well-established healthcare infrastructure. The infrastructure facilitates the creation, testing, and generalized use of novel treatments such as using mTOR inhibitors.

Many pharmaceutical and biotechnology businesses are leading the way in mTOR inhibitor research and development. These companies consistently allocate resources toward state-of-the-art research, clinical trials, and drug discovery, hence aiding in the development of novel and enhanced mTOR inhibitors. For instance, kidneys, liver, heart, lungs, pancreas, and intestine are the most frequently transplanted organs in the United States, according to data from the Centers for Disease Control and Prevention (CDC) for 2021. Approximately 75,000 people are on the active waiting list for organ transplants daily.

Future Market Scenario (2024 - 2031F)

With the advent of new and improved mTOR inhibitors, such as dual mTORC1/mTORC2 inhibitors the market is expected to grow at a fast pace. New age mTOR inhibitors show better treatment outcomes and fewer side effects than previous generation inhibitors.

Personalized treatment strategies that use mTOR inhibitors to target genetic alterations and pathways are becoming more and more popular as precision medicine gains traction.

Global regulatory bodies are building frameworks to speed up the development of specialized oncology departments, which is driving the expansion of mTOR Inhibitor market worldwide.

Numerous studies have demonstrated the ability of rapamycin and other rapalogs to postpone the development of cancer. Rapamycin prevents cancer in several dozen murine models in a robust and reproducible manner. Rapamycin delays the onset of cancer in genetically predisposed individuals who have received cancer treatment by slowing down the growth of tumors and the proliferation of cells.

Key Players Landscape and Outlook

The market for mTOR inhibitors is competitive with several major companies investing in the development of novel and cutting-edge treatments. The key players are making significant R&D investments to bring new medications to market as the need for mTOR inhibitors arises.

In February 2022, Cambrian Biopharma entered a strategic collaboration with Novartis. Under the partnership, Novartis supplied innovative compounds specifically designed to target the mTOR pathway for research and development purposes.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global mTOR Inhibitors Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Type
- 4.2.1. Rapamune
- 4.2.2. Afinitor
- 4.2.3. Torisel
- 4.2.4. Zortress
- 4.2.5. Omipalisib
- 4.2.6. Others
4.3. By Application
- 4.3.1. Cancer
- 4.3.2. Immunosuppression
- 4.3.3. Organ Transplantation
- 4.3.4. Others
4.4. By End-user
- 4.4.1. Hospital Pharmacies
- 4.4.2. Retail Pharmacies
- 4.4.3. Online Pharmacies
- 4.4.4. Others
4.5. By Region
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia-Pacific
- 4.5.4. South America
- 4.5.5. Middle East and Africa
4.6. By Company Market Share (%), 2023

5. Global mTOR Inhibitors Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Type
  - 5.1.2.1. Rapamune
  - 5.1.2.2. Afinitor
  - 5.1.2.3. Torisel
  - 5.1.2.4. Zortress
  - 5.1.2.5. Omipalisib
  - 5.1.2.6. Others
- 5.1.3. By Application
  - 5.1.3.1. Cancer
  - 5.1.3.2. Immunosuppression
  - 5.1.3.3. Organ Transplantation
  - 5.1.3.4. Others
- 5.1.4. By End-user
  - 5.1.4.1. Hospital Pharmacies
  - 5.1.4.2. Retail Pharmacies
  - 5.1.4.3. Online Pharmacies
  - 5.1.4.4. Others
- 5.1.5. United States*
  - 5.1.5.1. Market Size & Forecast
  - 5.1.5.1.1. By Value
  - 5.1.5.1.2. By Volume
  - 5.1.5.2. By Type
  - 5.1.5.2.1. Rapamune
  - 5.1.5.2.2. Afinitor
  - 5.1.5.2.3. Torisel
  - 5.1.5.2.4. Zortress
  - 5.1.5.2.5. Omipalisib
  - 5.1.5.2.6. Others
  - 5.1.5.3. By Application
  - 5.1.5.3.1. Cancer
  - 5.1.5.3.2. Immunosuppression
  - 5.1.5.3.3. Organ Transplantation
  - 5.1.5.3.4. Others
  - 5.1.5.4. By End-user
  - 5.1.5.4.1. Hospital Pharmacies
  - 5.1.5.4.2. Retail Pharmacies
  - 5.1.5.4.3. Online Pharmacies
  - 5.1.5.4.4. Others
- 5.1.6. Canada
- 5.1.7. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Type
6.2. By Application
6.3. By End-user
6.4. By Region

7. Macro Environment and Industry Structure

7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework & Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. AbbVie Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Astra Zeneca PLC
13.3. Bayer AG
13.4. Boehringer Ingelheim International Gmbh
13.5. Abott Inc.
13.6. Bristol-Myers Squibb Co
13.7. Pfizer Inc.
13.8. Merck & Co., Inc.
13.9. Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
13.10. F. Hoffmann-La Roche Ltd
13.11. Novartis AG
13.12. Sanofi S A
13.13. Eisai Co. Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

mTOR阻害剤の世界市場の評価：タイプ・用途・エンドユーザー・地域別の機会および予測 (2017年～2031年)

mTOR Inhibitors Market Assessment, By Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のmTOR阻害剤市場の展望

第5章世界のmTOR阻害剤市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global mTOR Inhibitors Market Outlook, 2017-2031F

5. Global mTOR Inhibitors Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework & Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

mTOR阻害剤の世界市場の評価：タイプ・用途・エンドユーザー・地域別の機会および予測 (2017年～2031年)

mTOR Inhibitors Market Assessment, By Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のmTOR阻害剤市場の展望

第5章 世界のmTOR阻害剤市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global mTOR Inhibitors Market Outlook, 2017-2031F

5. Global mTOR Inhibitors Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework & Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のmTOR阻害剤市場の展望

第5章世界のmTOR阻害剤市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項